The Curbsiders Internal Medicine Podcast cover image

#342 Checkpoint Inhibitors: The power, and adverse effects, of immunotherapy (ACP 2022)

The Curbsiders Internal Medicine Podcast

00:00

What's the Difference Between Infusion Reactions and Non-Hodgkin Lumthoma?

You'll see it less commonly, but very importantly, in hodgkin lumthoma. But i would say that the practising inturnist is going to see this in lung cancer. And then let's not forget melanoma. Melanoma and renal cell have long been understood as emunologically active tumors. The good thing we want to inflame is the cancer. I mean, ta an lead to long term disease control, even cure. What does it actually look like for patients? A wat, what kind of experience do they have receiving these treatments? So molly, it's very different than traditional cemo theraby a, and it's even different then than

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app